A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- Sponsors National Vaccine & Serum Institute
Most Recent Events
- 05 Jun 2022 Planned End Date changed from 1 May 2028 to 1 Jun 2028.
- 05 Jun 2022 Planned primary completion date changed from 1 May 2028 to 1 Jun 2028.
- 05 Jun 2022 Status changed from not yet recruiting to recruiting.